Repligen
RGEN
#2039
Rank
A$14.10 B
Marketcap
A$250.53
Share price
-0.46%
Change (1 day)
8.10%
Change (1 year)
Categories

Repligen (RGEN) - Total debt

Total debt on the balance sheet as of September 2025 : A$1.04 Billion

According to Repligen 's latest financial reports the company's total debt is A$1.04 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Repligen - Total debt on balance sheet (from 2004 to 2025)

Total debt by year

Year Total debt Change
2024-12-31A$1.10 B5.6%
2023-12-31A$1.04 B68.09%
2022-12-31A$0.62 B23.1%
2021-12-31A$0.50 B40.97%
2020-12-31A$0.35 B-4.76%
2019-12-31A$0.37 B156.02%
2018-12-31A$0.14 B15.55%
2017-12-31A$0.12 B-3.81%
2016-12-31A$0.13 B
2005-03-31A$0.15 M36.5%
2004-03-31A$0.11 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Novavax
NVAX
A$0.37 B-63.54%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
A$0.91 B-12.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
A$0.64 B-37.81%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
A$31.49 B 2,924.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
A$53.92 B 5,079.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$77.14 B 7,309.41%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$91.96 B 8,733.05%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
A$0.59 B-42.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
A$38.42 M-96.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
A$3.97 B 281.59%๐Ÿ‡บ๐Ÿ‡ธ USA